KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) FCF Margin (2016 - 2025)

Emergent BioSolutions' FCF Margin history spans 15 years, with the latest figure at 44.18% for Q4 2025.

  • For Q4 2025, FCF Margin rose 8537.0% year-over-year to 44.18%; the TTM value through Dec 2025 reached 21.11%, up 1434.0%, while the annual FY2025 figure was 21.11%, 1566.0% up from the prior year.
  • FCF Margin reached 44.18% in Q4 2025 per EBS's latest filing, up from 0.82% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 85.8% in Q2 2024 to a low of 116.74% in Q1 2023.
  • Average FCF Margin over 5 years is 0.91%, with a median of 5.31% recorded in 2022.
  • Peak YoY movement for FCF Margin: tumbled -10014bps in 2023, then soared 11963bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 17.0% in 2021, then plummeted by -351bps to 42.67% in 2022, then surged by 118bps to 7.48% in 2023, then plummeted by -650bps to 41.19% in 2024, then surged by 207bps to 44.18% in 2025.
  • Per Business Quant, the three most recent readings for EBS's FCF Margin are 44.18% (Q4 2025), 0.82% (Q3 2025), and 76.51% (Q2 2025).